08:00 , Jan 7, 2016 |  BC Innovations  |  Tools & Techniques

Islets of hope

The idea of using islet cell transplantation to treat diabetes has been simmering on the back burner for the last 15 years, with progress limited by two key obstacles: a shortage of donor cells, and...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

Cellectis gene/cell therapy, genomics news

In February, Cellectis' Cellartis AB subsidiary announced that is participating in the EU's Innovative Medicines Initiative (IMI) Mechanism based Improved Prediction of Drug-Induced Liver Injury (MIP-DILI) project. The consortium has a €32 million ($42.4 million)...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Horizon Discovery Ltd. gene/cell therapy, functional genomics news

Horizon joined the 4D Cell Fate consortium, which is researching the regulation of stem cell reprogramming and differentiation at the epigenetic level. Horizon will use its GENESIS recombinant adeno-associated virus (rAAV) gene editing technology to...
08:00 , Nov 14, 2011 |  BC Week In Review  |  Company News

Cellartis, Cellectis deal

Cellectis completed its acquisition of Cellartis, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1 million ($39.9 million). Cellartis shareholders received 1.9 million Cellectis shares valued at...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Company News

Cellartis, Cellectis deal

Cellectis said shareholders at its general meeting approved the acquisition of Cellartis in a cash and stock deal valued at €27.3 million ($38.4 million). Cellartis shareholders will receive 1.9 million Cellectis shares valued at €10.9...
08:00 , Feb 23, 2009 |  BC Week In Review  |  Company News

Cellartis, AstraZeneca deal

The partners will develop drug safety and screening systems based on human embryonic stem cell (hESC) derived hepatocytes and cardiomyocytes under an expanded research deal to explore the differentiation potential of hESCs. The companies will...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Company News

Cellartis, Novo Nordisk deal

The partners will develop insulin-producing cells from human stem cells to treat diabetes. Novo Nordisk will receive a non-exclusive license to Cellartis' human embryonic stem cell (hES) technology. The pharma will have exclusive, worldwide rights...
08:00 , Feb 5, 2007 |  BC Week In Review  |  Company News

ES Cell International, ITI Life Sciences deal

ES Cell International Pte. Ltd. , Singapore   ITI Life Sciences , Dundee, U.K.   Business: Gene/Cell therapy   ITI received non-exclusive rights to two of ES Cell’s U.K. patents covering methods of human embryonic...
08:00 , Jan 29, 2007 |  BC Week In Review  |  Company News

Cellartis, ITI Life Sciences, University of Glasgow deal

ITI awarded £9.5 million ($18.6 million) to Cellartis and the university to develop an automated process to produce human embryonic stem cells (hES) for use in drug discovery. The amount that Cellartis will receive is...
07:00 , Sep 4, 2006 |  BC Week In Review  |  Company News

Cellartis, NovaThera deal

The companies partnered to develop and commercialize stem cell therapies for expansion and differentiation of stem cells into lung and bone tissue. The companies will jointly pursue commercial applications resulting from the deal. Cellartis AB...